Condition: Advanced Esophageal Squamous Cell Carcinoma · Sponsor: Nanfang Hospital, Southern Medical University
Penpulimab plus chemotherapy with or without Anlotinib as first-line therapy for patients with advanced esophageal squamous cell carcinoma (Answer): A randomized two-arm clinical study.
This description comes directly from the study's public registry record.
wei wang · 020-61642136 · wwei9500@smu.edu.cn
Always discuss trial participation with your own doctor first.
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05214222